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Abstract: The epithelial sodium channel (ENaC) plays critical roles in maintaining fluid and
electrolyte homeostasis and is located in the aldosterone-sensitive distal nephron (ASDN).
We previously found that Nedd4-2 C2 knockout (KO) mice showed salt-sensitive hypertension with
paradoxically enhanced ENaC gene expression in ASDN under high oral salt intake. Eplerenone (EPL),
a selective aldosterone blocker, is a promising therapeutic option for resistant or/and salt-sensitive
hypertension. We examined the effect of EPL on Nedd4-2 C2 KO mice with respect to blood
pressure, metabolic parameters, and molecular level changes in ASDN under high oral salt intake.
We found that EPL failed to reduce blood pressure in KO mice with high oral salt intake and
upregulated ENaC expression in ASDN. Thus, salt-sensitive hypertension in Nedd4-2 C2 KO was
EPL-resistant. Gene expression analyses of laser-captured specimens in ASDN suggested the presence
of non-aldosterone-dependent activation of ENaC transcription in ASDN of Nedd4-2 C2 KO mice,
which was abolished by amiloride treatment. Our results from Nedd4-2 C2 KO mice suggest that
enhanced ENaC gene expression is critically involved in salt-sensitive hypertension under certain
conditions of specific enzyme isoforms for their ubiquitination.
Keywords: salt sensitivity; hypertension; Nedd4-2 C2; eplerenone; amiloride; resistant hypertension
1. Introduction
Salt sensitivity and hypertension are major human health problems because cardiovascular
morbidity and mortality due to hypertension are increasing worldwide [1–3]. Recent clinical practice
guidelines for managing hypertension in various countries indicate that appropriate blood pressure
lowering is necessary for reducing cardiovascular mortality [4–7]. “The lower, the better” strategies
for blood pressure management have been validated by cumulative clinical trials [8] and subsequent
systematic reviews [9]. The main pharmacological therapeutic targets for hypertension include the
renin-angiotensin system, sodium channels in renal tubules, and increased vascular tone in peripheral
arteries, which are treatable by angiotensin-converting enzyme inhibitors, angiotensin type I receptor
blockers, diuretics (thiazide derivatives), and calcium channel blockade, respectively. Among subjects
with hypertension, some failed to show adequate improvement despite appropriate prescription of
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the abovementioned basic representative anti-hypertensive drugs, a condition known as resistant
hypertension [10,11]. Therefore, treatments for resistant hypertension are currently being studied
as therapeutic options in clinical hypertension [12]. High oral salt intake in rural northern Japan
and a higher prevalence of hypertensive disease have been reported in previous hypertension
studies [13,14], and subsequent global epidemiological studies have supported this relationship [15].
Excessive oral salt intake in subjects with salt sensitivity results in hypertension and is thought to be
involved in the pathophysiological basis of resistant hypertension [16]. Eplerenone and spironolactone
are therapeutic options for subjects with resistant hypertension, suggesting that residual activation
of aldosterone signaling in distal tubules is the pathophysiological basis of this condition [17–20].
Recently, we used Nedd4-2 C2 knock out (KO) mice to demonstrate that loss of the Nedd4-2 C2
isoform causes salt-sensitive hypertension under conditions of high dietary salt intake in vivo [21].
We found and reported the enhancement of both epithelial sodium channel (ENaC) expression and
transcription along aldosterone sensitive distal nephrnon (ASDN) despite high oral salt intake by
Nedd4-2 C2 KO mice. ENaCs are ion transporters that play a pivotal role in sodium transport in the
terminal nephron and are representative aldosterone-inducible proteins (AIPs). The present study
aimed to elucidate the effect of eplerenone (EPL) and amiloride in Nedd4-2 C2 KO mice, as well as the
molecular mechanism underlying tubular-specific activation of ENaC in this genetically engineered
model of salt-sensitive hypertension.
2. Results
2.1. Metabolic Data in Nedd4-2 C2−/− Mice
The Nedd4-2 C2 domain is encoded by exon 2 in chromosome 18 of mice, and Nedd4-2 C2
KO mice show salt-sensitive hypertension under high oral salt intake, as reported previously [21].
There were no significant differences between the body weights of Nedd4-2 C2 KO mice and their WT
(wild type) littermates, as shown in Table 1.
Table 1. Characteristics of body weight (BW) between day 0 and day 10.
WT Littermates Nedd4-2 C2−/− (KO)
p 1
NS (n = 8) HS (n = 8) HS + EPL(n = 7) HS (n = 9)
HS + EPL
(n = 9)
HS + EPL + AML
(n = 8)
BW on day 0 28.50 ± 0.53 27.42 ± 1.17 26.78 ± 0.98 26.75 ± 0.93 27.69 ± 1.09 29.76 ± 0.68 0.2133
BW on day10 29.43 ± 0.53 28.02 ± 1.09 26.69 ± 1.30 27.86 ± 0.60 26.80 ± 1.06 28.59 ± 0.40 0.2584
1 Analyzed by one-way analysis of variance (ANOVA).
We measured systolic blood pressure (SBP) using the tail-cuff method. The average SBP was
lower in WT littermates than that in Nedd4-2 C2 KO mice (107.8 ± 0.5 mmHg vs. 112.6 ± 0.7 mmHg,
p < 0.001). EPL was able to reduce the SBP in WT littermates (107.8 ± 0.5 mmHg vs. 101.0 ± 0.5
mmHg, p < 0.001); however, no significant blood pressure reduction was observed in Nedd4-2 C2
KO mice (112.6 ± 0.7 mmHg vs. 116.2 ± 0.7 mmHg, p < 0.001). Thus, Nedd4-2 C2 KO mice showed
EPL-resistant hypertension. Amiloride (AML) had a clear demoting effect in Nedd4-2 C2 KO mice
with HS (high salt) + EPL (102.2 ± 0.5 mmHg vs. 116.2 ± 0.7 mmHg, p < 0.01) as shown in Figure 1a.
In all groups, SBP was elevated after 3 days of a high-salt diet, as shown in Figure 1b.
Water intake (WI) and urine volume (UV) were measured daily. WI increased after 2 days
of high-salt diet in KO mice and UV increased after 3 days in KO mice, as shown in Figure 2a,b.
Based on the body weight (BW) the average WI on a high-salt diet was 0.62 ± 0.02 g/day/gBW
in WT littermates and 1.30 ± 0.12 g/day/gBW in KO mice. The average UV under high-salt diet
was 0.34 ± 0.02 g/day/gBW in WT littermates and 0.85 ± 0.12 g/day/gBW in KO mice as shown
Figure 2c,d. For both WI and UV, there was a significant increase in KO mice compared to that in WT
littermates, and there was no significant effect on WI and UV with EPL. In contrast, AML decreased
both WI and UV in KO mice, similar to those in WT littermates.
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Figure 1. Systolic blood pressure (SBP) measured using the tail-cuff method. (a) Average SBP in each 
group for whole experimental periods analyzed by one-way ANOVA; (b) Average SBP on days 0, 3, 
7, and 10 in each group analyzed by two-way repeated measured ANOVA. Data are from wild-type 
(WT) mice on a normal salt diet (NS) (n = 8), wild-type mice on a high-salt diet (n = 8), wild-type mice 
on a high-salt plus eplerenone (EPL) diet (n = 3), Nedd4-2 C2 knock out (KO) mice on a high-salt diet 
(n = 9), Nedd4-2 C2 KO mice on a high-salt (HS) plus EPL diet (n = 9), and Nedd4-2 C2 KO mice on a 
high-salt plus EPL diet, treated with amiloride (AML) (n = 4). * p < 0.01 compared with WT NS, WT 
HS, WT HS + EPL, KO HS, and KO HS + EPL + AML; ** p < 0.05 compared with WT NS, WT HS, WT 
HS + EPL, KO HS + EPL, and KO HS + EPL + AML; *** p < 0.05 compared with WT NS, WT HS + EPL, 
KO HS, KO HS + EPL, and KO HS + EPL + AML; **** p < 0.01 compared with WT HS, KO HS, and KO 
HS + EPL. # p < 0.001 compared with WT NS, WT HS, WT HS + EPL, KO HS, and KO HS + EPL + 
AML; ## p < 0.001 compared with WT NS, WT HS + EPL, KO HS + EPL, and KO HS + EPL + AML; ### 
p < 0.01 compared with WT NS, WT HS + EPL, KO HS + EPL, and KO HS + EPL + AML; #### p < 0.01 
compared with KO HS, KO HS + EPL, and WT HS. 
Figure 1. Systolic bl od pressure (SBP) me red using the tail-cuff method. (a) Average SBP in each
group for whole experimental periods analyzed by one-way ANOV ; (b) Average SBP on days 0, 3,
7, and 10 in each group analyzed by two-way repeated measured ANOVA. Data are from wild-type
(WT) mice on a normal salt diet (NS) (n = 8), wild-type mice on a high-salt diet (n = 8), wild-type
mice on a high-salt plus eplerenone (EPL) diet (n = 3), Nedd4-2 C2 knock out (KO) ice on a high-salt
diet (n = 9), Nedd4-2 C2 KO mice on a high-salt (HS) plus EPL diet (n = 9), and Nedd4-2 C2 KO mice
on a high-salt plus EPL diet, treated with amiloride (AML) (n = 4). * p < 0.01 compared with WT
NS, WT HS, WT HS + EPL, KO HS, and KO HS + EPL + AML; ** p < 0.05 compared with WT NS,
WT HS, WT HS + EPL, KO HS + EPL, and KO HS + EPL + AML; *** p < 0.05 compared with WT NS,
WT HS + EPL, KO HS, KO HS + EPL, and KO S + EPL + AML; **** p < 0.01 compared with WT HS,
KO HS, and KO HS + EPL. # p < 0.001 compared with WT NS, WT HS, WT HS + EPL, KO HS, and KO
HS + EPL + AML; ## p < 0.001 compared with WT NS, WT HS + EPL, KO HS + EPL, and KO HS + EPL
+ AML; ### p < 0.01 compared with WT NS, WT HS + EPL, KO HS + EPL, and KO HS + EPL + AML;
#### p < 0.01 compared with KO HS, KO HS + EPL, and WT HS.
The urine Na+/K+ ratio was calculated daily by determining the urine sodium and potassium
concentrations. A significant reduction was observed in Nedd4-2 C2 KO mice compared to WT
littermates (5.06 ± 0.20 vs. 6.25 ± 0.16, p < 0.001), and EPL generally increased the Na+/K+ ratio both
in Nedd4-2 C2 KO mice and WT littermates (5.50 ± 0.16 and 6.41 ± 0.18), as shown in Figure 3a,b.
This indicates that sodium reabsorption via ENaCs was increased in Nedd4-2 C2 KO mice and that
EPL inhibited the function of renal outer medullary K+ channel (ROMK). AML inhibited ENaCs, and
the Na+/K+ ratio increased in Nedd4-2 C2 KO mice similar to that in WT littermates.Int. J. Mol. Sci. 2017, 18, 1250 4 of 13 
 
 
Figure 2. Water intake (WI) and urine volume (UV) measured daily. Averages of WI (a) or UV (b) 
from days 1 to 10 in each group. Analyzed by two-way repeated ANOVA. Averages of total WI (c) or 
UV (d) in each group analyzed by one-way ANOVA. Data are from wild-type mice on a high-salt diet 
(n = 4), wild-type mice on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n 
= 9), Nedd4-2 C2 KO mice on a high-salt plus EPL diet (n = 9), and Nedd4-2 C2 KO mice on a high-
salt plus EPL diet, treated with AML (n = 4). * p < 0.01 compared with WT HS, WT HS + EPL, and KO 
HS + EPL + AML; ** p < 0.01 compared with KO HS and KO HS + EPL. # p < 0.05 compared with WT 
HS, WT HS + EPL, and KO HS + EPL + AML; ## p < 0.05 compared with KO HS and KO HS + EPL. 
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UV (d) in each group analyzed by one-way ANOVA. Data are from wild-type mice on a high-salt diet 
(n = 4), wild-type mice on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n 
= 9), Nedd4-2 C2 KO mice on a high-salt plus EPL diet (n = 9), and Nedd4-2 C2 KO mice on a high-
salt plus EPL diet, treated with AML (n = 4). * p < 0.01 compared with WT HS, WT HS + EPL, and KO 
HS + EPL + AML; ** p < 0.01 compared with KO HS and KO HS + EPL. # p < 0.05 compared with WT 
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Figure 2. Water intake (WI) and urine volume (UV) measured daily. Averages of WI (a) or UV (b)
from days 1 to 10 in each group. Analyzed by two-way repeated ANOVA. Averages of total WI (c)
or UV (d) in each group analyzed by one-way ANOVA. Data are from wild-type mice on a high-salt
diet (n = 4), wild-type mice on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt
diet (n = 9), Nedd4-2 C2 KO mice on a high-salt plus EPL diet (n = 9), and Nedd4-2 C2 mice
on a high-salt plus EP diet, treated with AML (n = 4). * p < 0.01 compared with WT HS, WT HS
+ EPL, and KO S EPL + AML; ** p < 0.01 com ared with KO HS and KO HS + EPL. # p < 0.05
compared with WT HS, WT HS + EPL, and KO HS + EPL + AML; ## p < 0.05 compared with KO HS
and KO HS + EPL.
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Figure 3. Na+/K+ ratio calculated from urine Na+ and K+ concentrations. (a) Averages of total Na+/K+ 
ratio in each group analyzed by one-way ANOVA; (b) Averages of Na+/K+ ratio from days 1 to 10 in 
each group analyzed by two-way repeated ANOVA. Data are from wild-type mice on a high-salt diet 
(n = 4), wild-type mice on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n 
= 9), and Nedd4-2 C2 KO mice on a high-salt plus EPL diet (n = 9). * p < 0.01 compared with KO HS 
and KO HS + EPL; ** p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML. # p < 
0.05 compared with KO HS and KO HS + EPL; ## p < 0.05 compared with KO HS. 
2.2. Quantitative Analysis of Epithelial Sodium Channel (ENaC) Transcripts 
The expression of α, γ, and β ENaC in ASDN was measured by quantitative RT-PCR analysis of 
microdissected tissue samples. Compared with those in WT littermates, ENaC transcripts were 
increased significantly in Nedd4-2 C2 KO mice, and EPL did not suppress their expression in Nedd4-
2 C2 KO mice, as shown in Figure 4a–c. These results demonstrate that the activation of ENaC 
transcripts in ASDN occurs independently of aldosterone-mineral corticoid receptor (MR) signaling.  
Figure 3. Na+/K+ ratio calculated from urine Na+ and K+ concentrations. (a) Averages of total Na+/K+
ratio in each group analyzed by one-way ANOVA; (b) Averages of Na+/K+ ratio from days 1 to 10 in
each group analyzed by two-way repeated ANOVA. Data are from wild-type mice on a high-salt diet
(n = 4), wild-type mice on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet
(n = 9), and Nedd4-2 C2 KO mice on a high-salt plus EPL diet (n = 9). * p < 0.01 compared with KO
HS and KO HS + EPL; ** p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML.
# p < 0.05 compared with KO HS and KO HS + EPL; ## p < 0.05 compared with KO HS.
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of microdissected tissue samples. Compared with those in WT littermates, ENaC transcripts were
increased significantly in Nedd4-2 C2 KO mice, and EPL did not suppress their expression in Nedd4-2
C2 KO mice, as shown in Figure 4a–c. These results demonstrate that the activation of ENaC transcripts
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Figure 4. Total RNA abundance of (a) α ENaC; (b) β ENaC; (c) γ ENaC; and (d) ROMK in laser-
captured distal tubules/connecting tubules/cortical collecting ducts analyzed by one-way ANOVA. 
Data are from wild-type mice on a high-salt diet (n = 4), wild-type mice on a high-salt plus EPL diet 
(n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n = 4), and Nedd4-2 C2 KO mice on a high-salt plus 
EPL diet (n = 4). * p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML; ** p < 0.01 
compared with WT HS + EPL, KO HS, and KO HS + EPL; *** p < 0.01 compared with WT HS, KO HS, 
KO HS + EPL, and KO HS + EPL + AML; **** p < 0.01 compared with WT HS, WT HS + EPL, KO HS, 
and KO HS + EPL + AML; ***** p < 0.01 compared with WT HS, WT HS + EPL, KO HS + EPL, and KO 
HS + EPL + AML. # p < 0.01 compared with WT HS + EPL, KO HS, KO HS + EPL, and KO HS + EPL + 
AML; ## p < 0.01 compared with WT HS, WT HS + EPL, KO HS, and KO HS + EPL; ### p < 0.01 
compared with WT HS + EPL, KO HS + EPL, and KO HS + EPL + AML. 
2.3. Semi-Quantitative Analysis of ENaC Proteins 
We conducted staining to detect α, β, or γ ENaC expression in the kidneys by using specific 
antibodies and then determined the ratios of the stained area using the cell-count method. Semi-
quantitative histopathological examination of ENaCs revealed significant differences between the 
four groups, as shown in Figure 5a–c. Similar to the transcript analysis, there was significant elevation 
in the expression of each ENaC in KO mice, and EPL did not inhibit ENaC activation. Therefore, 
ENaC proteins were enhanced in KO mice and independent of aldosterone in ASDN. 
Figure 4. Total RNA abundance of (a) α ENaC; (b) β ENaC; (c) γ ENaC; and (d) ROMK in laser-captur d
distal tubule /connecting tubules/cortical collecting ducts analyzed by one-wa ANOVA. Data are
from wild-type mice on a high-salt diet (n = 4), wild-type mice on a high-salt plus EPL diet (n = 3),
Nedd4-2 C2 KO mice on a high-salt diet (n = 4), and Nedd4-2 C2 KO mice on a h gh-salt plus EPL diet
(n = 4). * p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML; ** p < 0.01 compared
with WT HS + EPL, KO HS, and + EPL; *** p < 0.01 compared with WT HS, KO HS, KO HS + EPL,
and KO HS + EPL + AML; **** p < 0.01 compared with WT HS, WT HS + EPL, KO HS, and KO HS + EPL
+ AML; ***** p < 0.01 compared with WT HS, WT HS + EPL, KO HS + EPL, and + AML.
# p < 0.01 compared with WT HS + EPL, KO HS, KO HS + EPL, and KO HS + EPL + AML; ## p < 0.01
compared with WT HS, WT HS + EPL, KO HS, and KO HS + EPL; ### p < 0.01 compared with WT HS
+ EPL, KO HS + EPL, and KO HS + EPL + AML.
2.3. Se i- uantitative nalysis of E aC Proteins
e t st i i g to detect α, β, or γ ENaC expression in the kidney by using
specific antibo ies an then determined the ratios of th st ined area using the cell-count method.
Semi-qu ntitative histopathological examinati n of ENaCs revealed significant differences t the
four groups, as sho n in Figure 5a–c. i ilar t t t ri t l sis, t re s i ificant elevation
in the expression of each ENaC in KO mice, and EPL did not inhibit ENaC activation. Therefore, ENaC
proteins were enhanc d in KO mice and independent of aldosterone in ASDN.
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Figure 5. Immunostaining of (a) α ENaC; (b) β ENaC; and (c) γ ENaC proteins by 
immunohistochemistry. Data are from wild-type mice on a high-salt diet (n = 4), wild-type mice on a 
high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n = 4), and Nedd4-2 C2 KO 
mice on a high-salt plus EPL diet (n = 4). * p < 0.01 compared with WT HS, WT HS + EPL, KO HS, and 
KO HS + EPL + AML; ** p < 0.05 compared with WT HS, WT HS + EPL, and KO HS + EPL; *** p < 0.05 
compared with WT HS + EPL and KO HS + EPL; **** p < 0.05 compared with WT HS + EPL, KO HS, 
and KO HS + EPL; ***** p < 0.05 compared with WT HS, KO HS, KO HS + EPL, and KO HS + EPL + 
AML. # p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML; ## p < 0.01 compared 
KO HS and KO HS + EPL. 
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probability, expression levels (regulation of expression), and membrane abundance (post-
translational modification). Genetic analyses of representative familial hereditary hypertension, 
known as Liddle syndrome, showed that the Proline-Tyrosine (PY) motif in the C terminus of ENaCs 
are commonly mutated, resulting in impaired protein-protein interactions with the Nedd4L 
Tryptophan-Tryptophan (WW) domain [22]. Failure of post-transcriptional modifications 
(ubiquitination) and subsequent trafficking to the proteasome result in persistent enhancement of 
membranous ENaC abundance and salt-sensitive hypertension. The total amount of sodium 
reabsorption in the terminal nephron depends on the ENaC expression level in the membrane, and 
accelerated reabsorption of intra-tubular sodium results in the development of salt-sensitive 
hypertension in vivo. Our detailed genetic analyses revealed the molecular diversity of the Nedd4-2/L 
gene in both humans and rodents, and two to three isoforms with and without the C2 domain in their 
N-terminus [23,24]. Subsequent analyses with the originally developed polyclonal antibodies for the 
C2 domain revealed specific expression in ASDN and colocalization of Nedd4-2/L with the C2 
domain and ENaCs in the terminal nephron [24,25]. Therefore, we hypothesized that the Nedd4-2 C2 
isoform functions as a critical ubiquitination enzyme involved in ENaC degradation in the ASDN. 
Isoform-specific gene targeting strategies showed that Nedd4-2 C2 KO mice are salt-sensitive 
and impair post-transcriptional modification of the ENaC proteins [21]. Our previous analyses 
demonstrated linearly enhanced expression of tubular ENaCs in accordance with genotype and oral 
salt intake, which is abolished by amiloride treatment. These findings suggest that the amplified 
intracellular sodium signaling resulted in ENaC gene transcription, which is known as excitation and 
transcription coupling of monovalent cations [26–29]. ENaC is considered a major effector of 
Figure 5. Im unostaining of (a) α ENaC; (b) β ENaC; and (c) γ ENaC proteins by
immunohistochemistry. Data are from wild-type mice on a high-salt diet (n = 4), wild-type mice
on a high-salt plus EPL diet (n = 3), Nedd4-2 C2 KO mice on a high-salt diet (n = 4), and Nedd4-2
C2 KO mice on a high-salt plus EPL diet (n = 4). * p < 0.01 compared with WT HS, WT HS + EPL,
KO HS, and KO HS + EPL + AML; ** p < 0.05 compared with WT HS, T HS + EPL, and KO HS + EPL;
*** p < 0.05 compared with WT HS + EPL and KO HS + EPL; **** p < 0.05 compared with WT HS + EPL,
KO HS, and KO HS + EPL; ***** p < 0.05 compared with WT HS, KO HS, KO HS + EPL, and KO HS +
EPL + AML. # p < 0.01 compared with WT HS, WT HS + EPL, and KO HS + EPL + AML; ## p < 0.01
compared KO HS and KO HS + EPL.
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3. Discussion
ENaCs are ion transporters expressed along the ASDN that play a pivotal role in handling
sodium in the terminal nephron. ENaC activity in the terminal nephron is regulated by open
probability, expression levels (regulation of expression), and membrane abundance (post-translational
modification). Genetic analyses of representative familial hereditary hypertension, known as Liddle
syndrome, showed that the Proline-Tyrosine (PY) motif in the C terminus of ENaCs are commonly
mutated, resulting in impaired protein-protein interactions with the Nedd4L Tryptophan-Tryptophan
(WW) domain [22]. Failure of post-transcriptional modifications (ubiquitination) and subsequent
trafficking to the proteasome result in persistent enhancement of membranous ENaC abundance
and salt-sensitive hypertension. The total amount of sodium reabsorption in the terminal nephron
depends on the ENaC expression level in the membrane, and accelerated reabsorption of intra-tubular
sodium results in the development of salt-sensitive hypertension in vivo. Our detailed genetic analyses
revealed the molecular diversity of the Nedd4-2/L gene in both humans and rodents, and two to three
isoforms with and without the C2 domain in their N-terminus [23,24]. Subsequent analyses with the
originally developed polyclonal antibodies for the C2 domain revealed specific expression in ASDN
and colocalization of Nedd4-2/L with the C2 domain and ENaCs in the terminal nephron [24,25].
Therefore, we hypothesized that the Nedd4-2 C2 isoform functions as a critical ubiquitination enzyme
involved in ENaC degradation in the ASDN.
Isoform-specific gene targeting strategies showed that Nedd4-2 C2 KO mice are salt-sensitive
and impair post-transcriptional modification of the ENaC proteins [21]. Our previous analyses
demonstrated linearly enhanced expression of tubular ENaCs in accordance with genotype and
oral salt intake, which is abolished by amiloride treatment. These findings suggest that the amplified
intracellular sodium signaling resulted in ENaC gene transcription, which is known as excitation
and transcription coupling of monovalent cations [26–29]. ENaC is considered a major effector of
aldosterone-mediated sodium reabsorption and fluid regulation. Therefore, ENaCs are representative
aldosterone-inducible proteins (AIP). Here, we demonstrated that the originally developed Nedd4-2
C2 KO mice show salt-sensitive hypertension, which was EPL-resistant (Figure 1). Detailed molecular
and histopathological analyses of the ASDN demonstrated that EPL treatment failed to suppress
both ENaC mRNA and protein expression in KO mice, whereas significant suppression of both
was observed in wild-type littermates (Figures 4 and 5). Analyses of the urine Na+/K+ ratios and
quantitative RT-PCR for laser-captured ASDN showed that ROMKs, which are also representative
AIPs and function in potassium secretion from ASDN, are suppressed by EPL treatment as expected
(Figures 3 and 4). Thus, we found that the action of EPL on the ASDN in Nedd4-2 C2 KO mice
deviated between ENaC and ROMK for electrolyte reabsorption and secretion. This may be tested
endocrinologically by measuring the aldosterone/corticosterone ratio, which is one of the limitations of
our current experiments. However we found no significant pathological change in the glomerulus by
light microscopic examinations, and thus urine albumin/protein secretion may be necessary to address
kidney functions for our current model of salt-sensitive hypertension with pharmacological treatment.
Aldosterone-independent activation of ENaC occurred in part due to the activation of the
tubular renin-angiotensin system. We previously demonstrated that a high-sodium diet upregulated
ENaC expression despite decreased plasma aldosterone concentrations [30]. Aldosterone-independent
upregulation of ENaC expression was also observed in Dahl salt-sensitive rats by Kakizoe et al.,
which was caused by the post-transcriptional cleavage of the inactivation domains of γ ENaC [31]
by channel-activating enzymes such as prostacin and furin [32–34]. Additionally, Nagase et al.
reported that Rac1, a rho family small GTP-binding protein, accelerated mineral corticoid receptor
transactivation independent of aldosterone [35]. These are considered among the various molecular
mechanisms involved in the paradoxical activation of ENaC under high-oral salt intake resulting in
salt sensitivity and hypertension. In this study, enhanced ENaC expression was observed despite EPL
treatment, whereas amiloride treatment successfully reduced blood pressure elevation and ENaC gene
expression in Nedd4-2 C2 KO mice with high oral salt intake and EPL treatment (Figures 1, 4 and 5).
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Moreover, detailed experiments using metabolic cages and daily urine collection revealed that both
water intake and urine volume abnormalities were fully restored to the normal state by amiloride
treatment (Figure 2). Amiloride treatment may also suppress sodium reabsorption through ENaC
itself and subsequent excitation-transcription coupling because of increased intracellular sodium,
which is independent of aldosterone-MR signaling. These results suggest that enhanced sodium
reabsorption through ENaC accelerated ENaC gene expression under loss of the specific Nedd4-2
isoform. Thus, the artificially genetic-engineered model of Nedd4-2 C2 loss revealed the underlying
mechanism of salt sensitivity, which may account for resistant hypertension. Further studies are
needed to examine the relationships between intracellular Na and ENaC gene expression (known as
excitation and transcription coupling of monovalent cations).
Interestingly, Melander et al. reported a subject with rs4149601, a common variant of human
Nedd4L formed by activating a cryptic splice site resulting in a frameshifted transcript [23],
which showed low renin salt-sensitive hypertension with significantly high cardiovascular mortalities
in a prospective clinical observational study [36,37]. Our in vitro analyses using Xenopus oocyte
heterologous expression systems revealed that subjects with the rs4149601 A to G mutation showed
impaired ENaC ubiquitination by the dominant-negative effects of specific Nedd4L isoforms [25].
However, whether subjects with rs4149601 A to G showed EPL resistance remains unclear. Our current
analyses showed that amiloride or similar pharmaceutical products such as triamterene are potent
effective options for treating resistant hypertension and salt sensitivity in order to correct and optimize
the tubular mechanism underlying the disease.
4. Materials and Methods
4.1. Metabolic Studies
Age-matched (15.2 ± 0.4 weeks old) male Nedd4-2 C2−/− mice (KO, n = 22) with a C57Bl6/J
background and their wild-type littermates (WT, n = 7) were kept for 10 days in individual metabolic
cages (SN-781, Shinano Manufacturing Co., Ltd., Tokyo, Japan) under controlled light, temperature,
and humidity after a 4-day habituation period. They were divided into five groups and received the
following diets: (1) WT mice were given a high-salt diet containing 8% NaCl (WT HS group, n = 4);
(2) WT mice were given a high-salt diet containing 8% NaCl plus eplerenone (WT HS + EPL group,
n = 3); (3) Nedd4-2 C2 KO mice were given a high-salt diet containing 8% NaCl (Nedd4-2 C2 KO HS
group, n = 9); (4) Nedd4-2 C2 KO mice were given a high-salt diet containing 8% NaCl plus eplerenone
(Nedd4-2 C2 KO HS + EPL group, n = 9); and (5) Nedd4-2 C2 KO mice were given a high-salt diet
containing 8% NaCl plus eplerenone and amiloride (Nedd4-2 C2 KO HS + EPL + AML group, n = 4).
Eplerenone (Pfizer, Inc., New York, NY, USA) was mixed into the diets at a dose of 1.25 g/kg of
chew). Amiloride (Biomol International, LP, Plymouth Meeting, PA, USA) was administered daily
by intra-abdominal injection at a dose of 1 mg/kg/day. Body weight (BW), water intake volume,
and urine volume were measured, and daily urine samples were collected. The concentrations
of urine sodium and potassium were measured using specific electrodes (Oriental Yeast Co., Ltd.,
Tokyo, Japan). Systolic blood pressure (SBP) and heart rate (HR) were recorded with the tail-cuff
method (MK-2000, Muromachi Kikai Co., Ltd., Tokyo, Japan) on days 0, 3, 7, and 10. On day 11,
the mice were sacrificed under anesthesia with sevoflurane, and their kidneys were dissected and
fixed for subsequent total RNA extraction and immunohistopathological analyses. Blood pressure
measurements were performed by two independent observers, who were blinded to the details of
the experiments. All animal experiments were performed in accordance with the guidelines of the
Animal Experiment Committee, Yokohama City University School of Medicine, and with approval of
the Animal Experiment Committee, Yokohama City University School of Medicine (F-A-14-088).
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4.2. Quantitative Reverese Transcriptase Polymerase Chain Reaction (RT-PCR) Analyses of ENaC Transcripts
Total RNA abundance of α, β and γ ENaCs in laser-microdissected late distal convoluted
tubules/connecting tubules/cortical collecting ducts (DCT/CNT/CCD) were measured by
quantitative RT-PCR analysis. We used TaqMan probes for mouse α ENaC (Mm00803386_m1), β ENaC
(Mm00441215_m1), and γ ENaC (Mm00441228_m1), all of which were purchased from Applied
Biosystems (Foster City, CA, USA). Kidney sections were stained with an anti-calbindin D28K antibody,
which was used as a marker of late DCT/CNT/CCD. Specific regions, expressing calbindin D-28K,
were carefully microdissected using a Leica CTR 6000 (Leica Microsystems, Wetzlar, Germany) and
collected into the cap of a 0.2-mL microtube. The total area of microdissection was 5,000,000 µm2
in each group. The tissues were then pooled for total RNA extraction using an RNeasy FFPE Kit
(Qiagen, Hilden, Germany). Synthesis of cDNA from total RNA was carried out using High-Capacity
RNA-to-cDNA Master Mix (Applied Biosystems). All PCRs were performed three times in duplicate.
4.3. Semi-Quantitative Immunohistopathological Analysis of ENaC Proteins
The area of ENaCs stained with anti-α, β, and γ ENaC antibodies (kindly provided by
Dr. Kitamura and Dr. Kakizoe, Yamanashi University, Kofu, Japan, Kumamoto University, Kumamoto,
Japan) in each DCT/CNT/CCD tubule selected was calculated using a computerized touch pen
device under a BZ-9000 microscope with Dynamic Cell Count BZ-HIC image analysis software
(Keyence, Osaka, Japan). These antibodies were originally developed using a specific epitope
common to those of Masilamani, et al. Specifically, the αENaC antibody was raised against
the N-terminal peptide (amino acids 46–68; NH2-LGKGDKREEQGLGPEPSAPRQPTC-COOH),
while the βENaC and γENaC antibodies were raised against the C-terminal peptides (βENaC:
amino acids 617–638; NH2-CNYDSLRLQPLDTMESDSEVEAI-COOH, γENaC: amino acids 629–650;
NH2-CNTLRLDRAFSSQLTDTQLTNEL-COOH) according to Masilamani, et al. [38]
4.4. Statistical Analyses
Data are expressed as the mean ± standard error (SE). All statistical analyses were performed
with SPSS version 21.0 software (SPSS, Inc., Chicago, IL, USA) and R 3.2.2 (R Foundation for Statistical
Computing, Vienna, Austria. Available online: https://www.R-project.org/). The relative abundance
of mouse transcripts and proteins in the kidney were compared statistically by one-way analysis of
variance (ANOVA) followed by Bonferroni’s multiple comparison tests. p < 0.05 was considered to
indicate statistical significance.
5. Conclusions
We found Nedd4-2 C2 KO mice show EPL resistant salt-sensitive hypertension and amiloride
treatment restore abberant enhancement of ENaC gene transcription along ASDN. This suggested
enhanced sodium reabsorption through ENaC itself accelerated ENaC gene expression under
loss of the specific Nedd4-2 isoform, which may account for one explanatory mechanism for
resistant hypertension.
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